Without much fanfare or notice, Liposcience Inc. of Raleigh, North Carolina tested the waters for an initial public offering (IPO) last month. It found market conditions unfavorable for its proposed offering of $92 million and deferred its IPO. Liposcience, with annual revenues of $18.5 million, markets a cardiovascular test built upon nuclear magnetic resonance (NMR) […]
To access this post, you must purchase The Dark Report.